LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressing medical needs.

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 billion from its type 2 diabetes drug Mounjaro and $1.

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years. The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance,

Shares of Eli Lilly & Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the stock’s worst day since March 15, 2021. The decline followed a disappointing fourth-quarter revenue outlook update,